Evidence map›Paper›PMID 24797372›Full record

Trial reportTransfusion2014

Transfusion-associated hepatitis before the screening of blood for hepatitis risk factors.

Ronald E Engle, Jens Bukh, Harvey J Alter, Suzanne U Emerson, Joni L Trenbeath, Hanh T Nguyen, Alicia Brockington, Tanaji Mitra, Robert H Purcell

Open access · greenAbstract readClinical Trial
In one paragraph

Trial report in Transfusion, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 25 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Hepatitis E: What We Think We Know.Clinical liver disease · 2020
    Review
  8. Article
  9. Article
  10. Role of humoral immunity against hepatitis B virus core antigen in the pathogenesis of acute liver failure.Proceedings of the National Academy of Sciences of the United States of America · 2018
    Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Ronald E EngleLaboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
Jens Bukh
Harvey J Alter
Suzanne U Emerson
Joni L Trenbeath
Hanh T Nguyen
Alicia Brockington
Tanaji Mitra
Robert H Purcell
National Institutes of Health · USNational Institute of Allergy and Infectious Diseases · USHvidovre Hospital · DKNational Institutes of Health Clinical Center · US

Funding

In Vivo And In Vitro Studies Of Hepatitis E VirusZIAAI000596 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI EMERSON, SUZANNE U · 2009 to 2014
$3.4M
A Prospective Study Of Anti-hepatitis C Virus Positive Blood DonorsZIACL002068 · CLC · CLINICAL CENTER · PI DE GIORGI, VALERIA · 2009 to 2025
$0k
Transfusion-related Infections Prospectively Studied (TRIPS)ZIACL002110 · CLC · CLINICAL CENTER · PI DE GIORGI, VALERIA · 2009 to 2025
$0k
Intramural NIH HHS Z99 AI999999
6 · The paper itself

Abstract

backgroundThe true incidence of transfusion-associated hepatitis (TAH) before blood screening is unknown. Our aims were to reevaluate blood recipients receiving unscreened blood and analyze hepatitis viruses circulating more than 45 years ago. STUDY DESIGN AND

methodsCryopreserved serum samples from 66 patients undergoing open heart surgery in the 1960s were reevaluated with modern diagnostic tests to determine the incidence of TAH and its virologic causes.

resultsIn this heavily transfused population receiving a mean of 20 units per patient of predominantly paid-donor blood, 30 of 66 (45%) developed biochemical evidence of hepatitis; of these, 20 (67%) were infected with hepatitis C virus (HCV) alone, four (13%) with hepatitis B virus (HBV) alone, and six (20%) with both viruses. Among the 36 patients who did not develop hepatitis, four (11%) were newly infected with HCV alone, nine (25%) with HBV alone, and one (3%) with both viruses. Overall, 100% of patients with hepatitis and 39% of those without hepatitis were infected with HBV and/or HCV; one patient was also infected with hepatitis E virus. The donor carrier rate for HBV and/or HCV was estimated to be more than 6%; contemporaneously prepared pooled normal human plasma was also contaminated with multiple hepatitis viruses.

conclusionTAH virus infections were a larger problem than perceived 50 years ago and HCV was the predominant agent transmitted. All hepatitis cases could be attributed to HCV and/or HBV and hence there was no evidence to suggest that an additional hepatitis agent existed undetected in the blood supply.

Indexed as

Blood TransfusionHepacivirusHepatitis BHepatitis B virusHepatitis CAdultAgedFemaleFollow-Up StudiesHepatitis EHepatitis E virusHumansMaleMiddle AgedRetrospective StudiesTime Factors

Identifiers

PMID24797372
PMCPMC5498987
OpenAlexW1927688270

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.